The 4th Annual Breath of the Hamptons, A Benefit for the Cystic Fibrosis Foundation,July 10, 2010
Reporting by Leah
The Cystic Fibrosis Foundation hosted the 4th Annual Breath of the Hamptons in Bridgehampton on Saturday, July 10, to help fund research for the cure of this genetic disease and to advance the development of new cystic fibrosis treatments.
The event was held outdoors at the beautiful home of Jeffrey Altman and offered fun and entertainment for singles, couples and the entire family, and cocktails and hors d’oeuvres, a buffet dinner by Fresh Flavors, live music by the Annie Morgan Band, and games and activities for kids of all ages, organized by camp counselors through the generosity of Hampton Country Day Camp for the fourth consecutive year.
A “Bid for a Cure,” with the proceeds benefiting a specific CF research program, was held during the event.
The Breath of the Hamptons started four years ago as a grassroots event by a few friends and has grown substantially andhadover300people attend this year’s event.
Breath of the Hamptons was sponsored by The Jeffrey A. Altman Foundation, and Laura and Keith Barket. The Co-Chairs and honorees were Stefanie Sacks Dec and Colleen Weis. Breath of the Hamptons brings us together in our daily fight to extend and improve the quality of life for those affected by Cystic Fibrosis.
About The Cystic Fibrosis Foundation
The CF Foundation, a non-profit donor-supported organization, is one of the most efficient organizations of its kind with 90 percent of every dollar of revenue raised being available to fund cystic fibrosis research, care and education programs. Charity Navigator, the countrys largest independent evaluator of charities, has given the CF Foundation its coveted four-star rating for sound fiscal management. The National Institutes of Health and many prominent publications have heralded the CF Foundations innovative business model, which fuels development programs and drug discovery.
Cystic Fibrosis is an inherited chronic disease that affects the lungs and digestive system of 30,000 children and adults in the U.S. with an additional 10,000,000 carriers of the defective CF gene.
For the first time, patients are taking drugs in clinical trials that address the basic genetic defect in CF, not just its symptoms. One of these first investigational drugs showed encouraging results in a preliminary clinical trial. It was well tolerated and in a a subset of CF patients, reduced sweat chloride levels-a key indicator of CF.
The FDA recently approved a new inhaled antibiotic which offers a much needed antibiotic alternative for CF patients who battle recurrent lung infections and develop resistance to existing antibiotics.
Research and clinical trials have yielded significant results and the median predicted age of survival continues its steady rise. Since 1955, the Foundation has extended the average life expectancy of those with CF from 5 years to 37 years of age.
For more information on the Cystic Fibrosis Foundation please visit www.cff.org.
